ReviewOncology and therapy2026

Neoadjuvant Therapy in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer: Recent Progress, Challenges, and Future Directions in the Era of TAR-200 and Enfortumab Vedotin Plus Pembrolizumab.

Giuseppe Di Lorenzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.